Valuation
- Market cap
- 524,837,000
- Revenue TTM
- $120,000
- Net income TTM
- $-220,240,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -183,533.34%
- Debt to equity
- -1.32
Trading
- Volume
- 3,000
- Avg volume
- 38,738
- Day's range
- $3.25 – $3.48
- Shares out
- 153,911,000
- Stochastic %K
- 33%
- Beta
- 1.12
- Analysts
- Strong Sell
- Price target
- $12.00
Company profile
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotec...
Show more
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 61 3 9826 0399
- Website
- https://opthea.com
- Address
- Level 9, 505 Little Collins Street, Melbourne, Australia
Latest news
No headlines yet.
